|
|
Cinfa launches Rosvacor in Qatar, offering new
therapeutic options for the
treatment of cardiovascular
diseases
(Doha, Qatar) - The Spanish pharmaceutical laboratory
Cinfa has launched its
new product Rosvacor
(Rosuvastatin) in Qatar.
This marks an important
milestone in Cinfa's
expansion in the
cardiometabolic area,
offering new therapeutic
options for dyslipidemia and
prevention of cardiovascular
diseases. Rosvacor is
available in doses of 5mg,
10mg, and 20mg.
Cinfa
has conducted this launch in
response to the increasing
prevalence of dyslipidemia
and cardiovascular events in
the Middle East, a region
where these diseases
represent a significant
public health challenge.
Dyslipidemia is a major
risk factor for
atherosclerotic
cardiovascular disease
(ACD), which includes
ischemic heart disease (IHD)
and strokes. In the UAE, IHD
and strokes are leading
causes of premature death,
responsible for
approximately 40% of all
deaths in the country.
Effective management of
dyslipidemia is crucial, as
it can significantly reduce
the progression of
atherosclerosis and
associated cardiovascular
diseases.
Rosuvastatin, the key
molecule in the treatment of
dyslipidemia, has been shown
to be effective in reducing
LDL cholesterol, thus
contributing to the
prevention of cardiovascular
diseases.
According to the
WHO, a 10% reduction in
serum cholesterol levels can
halve the risk of IHD in
40-year-old men over five
years, underscoring the
importance of medications
like Rosvacor in managing
dyslipidemia.
Strengthening the
Cardiometabolic Portfolio
The addition of Rosvacor
expands Cinfa's
cardiometabolic portfolio in
Qatar, which already
includes the following
medicines:
-
Atorcor (Atorvastatin)
-
Vanguard (Valsartan)
-
Vanguard Plus (Valsartan Hydrochlorothiazide)
-
Olmepress (Olmesartan)
-
Co-Olmepress (Olmesartan Hydrochlorothiazide)
-
Olmedine (Olmesartan Amlodipine)
-
Zetmol (Ezetimibe).
Cinfa's strategy in the region focuses on addressing the
alarming rise in diseases
such as diabetes,
hypertension, and other
cardiovascular disorders,
both in the Western and
Eastern worlds. Franc Vives,
Chief International Officer
at Cinfa, has emphasized the
importance of focusing on
these areas to provide
effective solutions to
patients, and has stated,
"everything related to
ischemic heart disease
treatment, diabetes,
hypertension, among others,
constitutes the core of our
strategy in the region". And
has added that “this
approach is clearly
reflected in the launch of
Rosvacor and the ongoing
expansion of our
cardiometabolic product
portfolio in Qatar.
According to our mission of
improving the health and
well-being of patients in
Qatar and beyond, always
focused on high quality,
safe and effective
medicines, and health
solutions.”
PRINT
THIS ARTICLE
|
